Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT05066139
Recruiting Not applicable

Multidisciplinary Evaluation of Elderly Patients With Digestive Cancer (EPODIG-G)

NCT05066139 · tracked via the Priya Life Science France tracker
Sponsor
Centre Paul Strauss
Phase
Not applicable
Started
2021-09-17
Last updated
2026-01-05

Condition(s) studied

Digestive System DiseaseNeoplasms

Investigational drug(s) / intervention(s)

EPODIG-G program (coordination of supportive care)

EPODIG-G program (coordination of supportive care): EPODIG-G program includes: a nutritional evaluation (laboratory tests: albumin, pre-albumin, C reactive protein and vitamin D dosage, nutritional status, Handgrip test, Simple Evaluation of Food Intake (SEFI), spontaneous food intake evaluation) ; a medication reconciliation ; physical therapy (Six Minute Walk Test)

Study summary

This is a monocentric, comparative, open-label, randomized parallel group study enrolling elderly subjects hospitalized in Strasbourg Europe Cancerology Institute (ICANS), starting chemotherapy or targeted therapy for the treatment of digestive cancer.

Eligibility

Sex
ALL
Min age
75 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients must be ≥ 75 years old * Performance status 0, 1 or 2 * Diagnostic of digestive cancer, all stages (adjuvant or metastatic), with an indication for chemotherapy treatment or targeted therapy for a treatment period of 24 weeks or more * Patients previously treated with one or several lines of chemotherapy for this digestive cancer are eligible * Estimated life expectancy ≥ 3 months * Patients able to speak, read and understand French * Signed informed consent from the patient * Patients must have a social security coverage Exclusion Criteria: * History of differentiated neuroendocrine tumors grade 1 or 2 (pancreas, small intestine) * Cancer currently being treated (except for hormone therapy) other than current digestive cancer * History of major surgery and/or curative radiation therapy during the last 4 weeks before inclusion * Patients unable to submit to medical follow-up for geographical, social or psychological reasons * Patients placed under guardianship

Primary outcome measure(s)

  • Impact of EPODIG-G program on treatment. — 24 weeks after treatment initiation
    Number of patients who benefit from all programmed treatment cycles at 24 weeks

Trial sites (1)

FacilityCityRegionStatus
Institut de cancérologie Strasbourg Europe Strasbourg France Recruiting

More Centre Paul Strauss trials in France

Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma Recruiting
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma Recruiting
Evolution of Hypofractionated Stereotactic Irradiation for Radio-Resistant Brain Metastases From D1-3-5 to D1-2-3 Starting soon
Post-TRaUmatic STress Disorder Induced by Gynecological Brachytherapy Recruiting
Identification of Genetic Determinants for Treatment Resistance/Sensitivity and/or Toxicity in Adjuvant Setting for HER2 Positive Breast Cancer Recruiting

Other trials for the same condition

A Study of JNJ-87890387 for Advanced Solid Tumors Recruiting
Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy Recruiting
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors Recruiting
Anatomical-Clinical Base of Adenocarcinoma Pancreatic Recruiting
A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05066139 on ClinicalTrials.gov ↗ ← All trials in France